Citations

Clear

950 citation(s) found for "Cohen, M".

Development and Validation of a Novel Conditional Event‐Free Survival Tool in Diffuse Large B‐Cell Lymphoma
Chen, Zhengming, Luan, Danny , Jørgensen, Rasmus Rask Kragh , El-Galaly, Tarec C., Nastoupil, Loretta J., Cerhan, James R. , Flowers, Christopher R., Link, Brian K., Lossos, Izidore S. , Stephens, Deborah M., Cohen, Jonathon, Nowakowski, Grzegorz, Bartlett, Nancy, Friedberg, Jonathan W. , Kahl, Brad S., Leonard, John P., Brown, Peter, Smedby, Karin E., Martin, Peter, El‐Galaly, Tarec Christoffer , Rask Kragh Jørgensen, Rasmus , Maurer, Matthew , El-Galaly, Tarec C , Cerhan, James R , Lossos, Izidore S , Habermann, Thomas , Jakobsen, Lasse Hjort , Maurer, Matthew J. , Nastoupil, Loretta J. , Flowers, Christopher R. , Link, Brian K. , Stephens, Deborah M. , Habermann, Thomas M. , Nowakowski, Grzegorz, Bartlett, Nancy L. , Kahl, Brad S. , Smedby, Karin E. , Jerkeman, Mats

Mayo Clinic

American Journal of Hematology | June 4, 2026 | Volume: 101 | Issue: 9 | Pages: 2137-2146

10.1002/ajh.70398 | PMID 42240061 Get It

ABSTRACT One quarter of patients with diffuse large B‐cell lymphoma (DLBCL) who achieve a complete response following front‐line therapy will eventually experience disease relapse. Existing prognostic models use baseline factors to predict outcomes from the start of initial therapy and are not intended for use following completion of treatment. We developed a conditional event‐free survival (cEFS) tool that predicts a patient's risk of lymphoma recurrence after completing front‐line therapy taking into consideration baseline risk characteristics plus the time the patient has been in remission. Model development used pooled and harmonized data from two observational cohorts and four randomized trials of patients with newly diagnosed DLBCL treated with immunochemotherapy and either achieving a complete response or not experiencing an event within 12 weeks of end of therapy. Cox proportional‐hazards regression modeling with backwards stepwise selection was utilized for model development. External validation was performed using a large independent data registry. In total, data from 2757 patients were used for model development. The risk of experiencing an event at a time point after having survived a period of time could be computed parsimoniously using four basic predictors: age, ECOG performance status grade, Ann Arbor stage, and lactate dehydrogenase level. C‐index in the model development cohort was 0.65 (95% CI, 0.63–0.68), compared to 0.64 (95% CI, 0.62–0.66) in the external validation cohort. We believe that this dynamic risk prediction tool will not only aid clinicians in providing data‐driven recommendations for surveillance, but also assist patients themselves with key decisions, such as family planning.
Age and Procedural Timing for Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial
Goel, Kashish , Lindman, Brian R. , Schwartz, Allan, Cohen, DE, Giustino, Gennaro, Oldemeyer, J. Bradley , Strote, Justin, Babaliaros, Vasilis, Devireddy, Chandan , Fischbein, Michael P. , Fearon, W F, Daniels, David, Spies, Christian, Shah, Pinak , Dahle, Thom, Apostolou, Dimitrios , Makkar, R, Davidson, Charles J. , Sheth, Tej, Sorajja, Paul , DeVries, James T. , Southard, J.H., Depta, Jeremiah P. , Pop, Andrei, Rinaldi, Michael J., Badr, Salem , Russo, Mark J., Wang, Yizhuo , Leon, Martin B. , Généreux, Philippe , Cohen, David J. , Schwartz, Allan , Cohen, David Jonathan , Babaliaros, Vasilis , Devireddy, Chandan M , Fearon, William F , Chhatriwalla, Adnan K , Suradi, Hussam , Shah, Pinak , Szerlip, Molly , Dahle, Thom , Apostolou, Dimitrios , Makkar, Raj , Davidson, Charles J. , Sorajja, Paul , DeVries, James T , Southard, Jeffrey , Depta, Jeremiah P , Badr, Salem , Guerrero, Mayra E , McCabe, James M , Pibarot, Phillippe , Wang, Yizhuo , Leon, Martin B. , Généreux, Philippe , Lindman, Brian R , Giustino, Gennaro , Babaliaros, Vasilis , Fearon, William F. , Makkar, Raj , Sheth, Tej , Rinaldi, Michael , Williams, Mathew , Russo, Mark J., Guerrero, Mayra

Mayo Clinic

Circulation: Cardiovascular Interventions | June 3, 2026 | Volume: 19 | Issue: 8 | Pages: No page available

10.1161/circinterventions.125.016370 | PMID 42233211 Get It

BACKGROUND: The EARLY TAVR trial (Evaluation of TAVR Compared to Surveillance for Patients with Asymptomatic Severe Aortic Stenosis) demonstrated that early transcatheter aortic valve replacement (TAVR) was superior to clinical surveillance (CS) in asymptomatic severe aortic stenosis. The relative impact of early TAVR versus CS strategy by age is unknown. METHODS: The study population of the EARLY TAVR trial was stratified into 4 age groups: 65 to 69 years (n=141), 70 to 74 years (n=263), 75 to 79 years (n=250), and ≥80 years (n=247). Associations between age and the trial primary end point of death, stroke, or unplanned cardiovascular hospitalization; the composite end point of death, stroke, or heart failure hospitalization; and its individual components were examined. Interaction tests evaluated whether the treatment effect of early TAVR versus CS differed by age. RESULTS: No interaction was detected between age and the treatment effect of early TAVR versus CS for the composites or individual outcomes. We observed lower stroke rates with early TAVR compared with CS in the youngest (65–69 years, absolute risk reduction, 13%; P =0.008) and oldest (≥80 years; absolute risk reduction, 12.3%; P =0.029) age groups. The absolute difference in heart failure hospitalization rates between the early TAVR and CS arms at 2 years was greatest in the oldest patients (≥80 years, 9.1%; 75–79 years, 5.9%; 70–74 years, 5.1%; 65–69 years, 4.4%). In the CS group, time to conversion to AVR was similar across all age groups (median, 11 months; P =0.73). Approximately one-third of younger patients (65–69 years) in the CS arm presented with acute valve syndrome at the time of conversion, the frequency of which tended to increase with age ( P =0.06). CONCLUSIONS: In the EARLY TAVR trial, the relative benefit of early TAVR over CS was consistent among all age groups. The greatest absolute reduction in stroke rate with early TAVR compared with CS appeared in the youngest and oldest groups, whereas reduction in heart failure hospitalization was most pronounced in the oldest patients. These data suggest that early TAVR should be considered in all age groups above 65 years. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03042104.
Mast cell score associates with wide-spread mast cell symptoms and comorbidities in patients with hEDS and HSD
Wilson, Frances C., Zangerle, Derek J. , Rozen, Lincoln E. , Fliess, Jessica J. , Darakjian, Ashley A. , Sacco, Keith , Hamilton, Charwan , Strandes, Max W , Puls, Alayna M , Hartmoyer, Cameron J. , Reyes, Sophia N. Witola , Menton, Stacey M. , Dudenkov, Daniel V. , Gonzalez-Estrada, A, Solomon, Sarah C., Stephens, Ina, Wang, Benjamin W.E., Botella, R, Zeman, Ashley M., Gajarawala, Shilpa , Wilson, Frances C , Sacco, Keith A , Witola Reyes, Sophia N , Gonzalez-Estrada, Alexei , Atwal, Paldeep S , Shufelt, Chrisandra L , Zeman, Ashley M , Knight, Dacre R T , Gajarawala, Shilpa , Bruno, Katelyn A , Fairweather, DeLisa , Gonzalez‐Estrada, Alexei , Solomon, Sarah Cohen, Shufelt, Chrisandra , Bruno, Katelyn A. , Fairweather, DeLisa

Mayo Clinic

No container title available | June 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.31.26354552 | PMID 42282176 Get It

Abstract Background Wide-spread mast cell (MC)-associated symptoms and MC activation syndrome (MCAS) are often reported in patients with hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD). The goal of this study was to develop a novel MC score based on 11 self-reported MC-related conditions with clinical and research utility to better understand MC symptoms in hEDS and HSD patients. Methods From November 1, 2019, to June 13, 2025, patients ( n =2,141) filled out an Intake Questionnaire at the Mayo Clinic Florida EDS Clinic that included 11 self-reported questions related to categories of MC-related conditions for a MC score ranging from 0/11 to 11/11. Based on the MC score distribution in hEDS and HSD patients, a MC score of 0-1 was considered a low MC score and ≥5 was considered a high MC score. Symptoms/comorbidities were compared between patients with high vs. low MC scores. Results From the 2,141 hEDS/HSD patients, 535 (25.0%) had a MC score ≥5 (Hi MC). MCAS-specific symptoms such as nausea and vomiting were reported more often in hEDS/HSD patients with a high vs. low MC score ( p <0.0001). Random clinical blood tryptase and urinary MC markers were not elevated in patients with high MC scores ( n =50/group), although high MC scores were found to significantly reduce urinary creatinine levels indicating that the protein used to normalize data was affected by MC activity. In contrast, random blood IgE, tryptase and major basic protein (MBP) by ELISA were increased in patients with high MC scores (e.g., IgE hEDS p =0.0004, HSD p =0.003). Of note, the percentage of patients reporting abuse or post-traumatic stress disorder was nearly doubled in patients with high vs. low MC scores (Abuse and PTSD: hEDS p < 0.0001; HSD p < 0.0001). Overall, 109/135 (80.7%) in hEDS and 129/135 (95.6%) in HSD reported more symptoms/comorbidities if they had a high MC score. Conclusions We found that hEDS/HSD patients with high MC scores self-reported more widespread symptoms/comorbidities and higher MC-related blood markers than patients with low MC scores indicating the utility of this tool to evaluate the level of widespread MC activity in hEDS, HSD and other patients.
Subclinical Optic Nerve Involvement in Radiologically Isolated Syndrome: Multimodal Detection and Diagnostic Impact
Lebrun‐Frénay, Christine , Landes-Château, Cassandre , Mondot, Lydiane , Cohen, Mikaël , Popolo, Margherita , Sèze, de , Bourre, Bertrand , Casez, Olivier , Kantarci, Orhun H. , Baillif, Stéphanie, Seze, Jerome De , Durand-Dubief, Françoise , Casez, Olivier , Kantarci, OH , Siva, Aksel , Baillif, Stephanie , Okuda, Darin T , Leocani, Letizia , Lebrun‐Frénay, Christine , Bourre, Bertrand , Cohen, Mikaël , Mondot, Lydiane , Durand‐Dubief, Françoise , Sıva, Aksel , Okuda, Darin T.

Mayo Clinic

Annals of Clinical and Translational Neurology | June 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/acn3.70441 | PMID 42227083 Get It

ABSTRACT Objectives We aimed to determine the frequency of subclinical optic nerve (ON) lesions using MRI, optical coherence tomography (OCT), and visual evoked potentials (VEP) in radiologically isolated syndrome (RIS), and to assess their diagnostic and prognostic significance. Methods We conducted a retrospective, multicenter study of 179 RIS individuals followed in clinical practice who met the 2023 RISC criteria. The diagnostic performance of the 2024 McDonald criteria, with and without optic nerve assessment, was evaluated and compared with that of the 2017 criteria. Associations with clinical conversion, comorbidities, and MRI disease activity were analyzed using multivariate models. Results Silent ON lesions appeared in 107/179 (59.8%) individuals, mainly detected by VEP (100/164; 61.0%) and OCT (69/118; 58.5%), with routine MRI identifying 31/166 (18.7%). During follow‐up, 71 (39.7%) had a first clinical event. The presence, laterality, or number of silent ON lesions did not correlate with clinical conversion, event type, or MRI activity. Younger age and the absence of comorbidities associated with other MRI lesions, rather than with ON lesions, were associated with clinical conversion. Including ON in the 2024 McDonald criteria increased sensitivity but decreased specificity, with 17/179 (9.5%) meeting dissemination‐in‐space criteria solely due to ON lesions. Interpretation Subclinical ON lesions are common in RIS and are mainly found by OCT and VEP, not routine MRI. Including ON increases sensitivity but does not predict clinical conversion and may lower specificity. These findings suggest cautious interpretation of ON and support a multimodal assessment approach in RIS.
Spinal cord imaging for multiple sclerosis: Advances, priorities, and opportunities
Laule, Cornelia , Cohen-Adad, Julien, Witt, Atlee , Luca, Gabriele C. De, Granziera, Cristina , Keegan, B. Mark , Kerbrat, Anne , Klawiter, Eric C, Kolind, Shannon , O’Grady, Kristin P. , Oh, Jiwon, Sivakolundu, Dinesh K. , Smith, Seth A, Vavasour, Irene M, Mainero, Caterina , Alonso-Ortiz, Eva, Krieger, Stephen , Li, David , Shinohara, Russell T, Henry, Roland G, Cooperative, North American Imaging in Multiple Sclerosis (NAIMS), Witt, Atlee A , De Luca, Gabriele C , Bagnato, Francesca R. , Gauthier, Susan A , Bakshi, Rohit , Beck, Erin S , Krieger, Stephen , Keegan, B Mark , Kollind, Shannon H , Granziera, Cristina , O'Grady, Kristin P , Cohen-Adad, Julien , DeLuca, Gabriele C. , Kerbrat, Anne , Klawiter, Eric C. , Oh, Jiwon , Schilling, Kurt G. , Smith, Seth A. , Tozlu, Ceren , Vavasour, Irene M. , Alonso‐Ortiz, Eva , Brier, Matthew R. , Hemond, Christopher C , Li, David K.B. , Shinohara, Russell Taki , Henry, Roland G.

Mayo Clinic

Multiple Sclerosis Journal | June 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/13524585261444600 | PMID 42224274 Get It

The spinal cord plays a central role in the pathophysiology and clinical manifestations of multiple sclerosis (MS), yet remains under-studied compared with the brain. This review summarizes key insights from the 2025 North American Imaging in MS Spinal Cord Imaging Workshop, highlighting recent advances, ongoing challenges, and future opportunities in MS spinal cord imaging. We review pathological studies and outline the clinical relevance of spinal cord lesions and atrophy for diagnosis, prognosis, and disease monitoring, highlighting emerging biomarkers of progression independent of relapse activity. Correlations between magnetic resonance imaging, histopathology, and clinical outcomes support the validation and translational potential of advanced spinal cord imaging techniques. Finally, we discuss spinal cord–specific processing pipelines and reproducibility challenges. Collectively, these insights underscore the need to integrate advanced and quantitative spinal cord imaging into clinical trials, research studies, and—when feasible—clinical care, to fully capture the extent of MS pathology, and ultimately improve patient outcomes.
Disease-modifying treatment preferences and decision-making in a multiple sclerosis randomized and observational clinical trial (DELIVER-MS)
Tallantyre, Emma C , Planchon, Sarah M. , Howard, Harriet, Mays, John, Frowd, Nadia, Cohen, Jeffrey A. , Hersh, Carrie M. , Miller, Deborah , Dever, Meredith , Gray, Emma H., LaRocca, Nicholas G., Bale, Clare , Covey-Crump, Gwen, Alvarez, Enrique, Craner, Matt, Freeman, L, Frost, N, Hobart, JC, Hutton, George J, Hyland, Megan , Kalra, S, Kannan, Meena, Kantarci, OH , Lashley, Daniel, Lily, Oliver, Mahad, D, Nicholas, J, Nicholas, R, Paling, David, Pearson, Owen , Rice, Claire M , Samudralwar, Rohini, Schmalstieg, William F., Singh, M, The, E Zune, Zabeti, Aram , Love, Thomas E, Gunzler, Douglas , Liu, Y, GERRY, STEPHEN, Evangelou, N, Hersh, Carrie M , Miller, D M , Nakamura, Kunio , Goldman, Myla D , Harding, Katharine E , Hobart, Jeremy , Kalra, Seema , Nicholas, Richard , Pearson, Owen R , Rice, Claire M , Weinstock‐Guttman, Bianca , Evangelou, Nikos , Ontaneda, Daniel , Cohen, Jeffrey Allen , Tallantyre, Emma Clare , Coles, Alasdair J. , Covey-Crump, Gwen L , Arun, Tarunya , Brownlee, Wallace J , Craner, Matthew J., Freeman, Leorah A. , Goldman, Myla , Gupta, Rajesh , Hutton, George J., Kantarci, Orhun H. , Mahad, Don , Paling, David , The, Ei Zune , Love, Thomas E.

Mayo Clinic

Multiple Sclerosis Journal | May 31, 2026 | Volume: 32 | Issue: 7 | Pages: 722-736

10.1177/13524585261449988 | PMID 42218617 Get It

Background: There is growing support for high-efficacy disease-modifying therapy (DMT) in multiple sclerosis (MS), but escalation (ESC) approaches remain common. Objective: To describe decision-making in a pragmatic trial of early high-efficacy treatment (EHT) versus ESC. Methods: DELIVER-MS is a multi-center, pragmatic, randomized controlled trial (RCT) with a parallel observational study (OBS), which enrolled treatment-naïve people with RRMS in 31 UK/US sites. Primary outcome was as follows: 36-month brain volume loss according to initial treatment approach (EHT vs. ESC). Stepwise multivariable logistic regression was used to predict participation in RCT versus OBS and choice of EHT versus ESC within the OBS cohort. Results: In total, 816 people with MS were enrolled. Participants declined randomization due to preference for a particular DMT (85%), efficacy concerns (20%), and safety concerns (9%). RCT versus OBS participation was associated with lower relapse rate ( p = 0.043) and greater brain parenchymal fraction ( p = 0.002). Among 374 in the OBS cohort, 125 (33%) chose ESC and 249 (67%) chose EHT. People commencing EHT had higher education attainment ( p < 0.001) and relapse rate ( p = 0.025). Conclusion: Baseline DELIVER-MS data demonstrate that participants with milder disease are more likely to participate in RCT. The choice of EHT versus ESC was associated with demographic factors and disease activity. Clinical trial registration: NCT03535298
Artificial intelligence comparison of Google MedGemma and ChatGPT-5 in expert-reviewed gastrointestinal and genitourinary oncology cases.
Zidan, Ali , El-Sururi, Mousa, Belbase, Avi, Pelster, Meredith, Bouferraa, Youssef , Lin, Daniel , Cohen, Steven J., Eslinger, Cody , Garmezy, Benjamin, Maughan, Benjamin L., Odabashian, Roupen, Bashir, Babar , Pelster, Meredith S. , Khorana, Alok A. , Xie, Hao , Maughan, Benjamin L. , Odabashian, Roupen

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.e15509 Get It

e15509 Background: Large language models (LLMs) are increasingly explored for oncology decision support, yet comparative evidence evaluating medical-specific versus general-purpose LLMs using expert-reviewed clinical cases is limited. We compared a medical-specific LLM (Google MedGemma 27B) with a general-purpose LLM (ChatGPT-5) using gastrointestinal (GI) and genitourinary (GU) oncology vignettes. Methods: This cross-sectional study evaluated 32 de-identified oncology vignettes (26 GI, 6 GU) created by a U.S. board-certified medical oncologist and informed by real-world cases. Vignettes included text-only information on the clinical context, description of pathology, tumor staging, biomarkers, and relevant comorbidities. Both LLMs were prompted to provide National Comprehensive Cancer Network(NCCN) guideline-based treatment recommendations, monitoring strategies, maintenance therapy considerations, and references, along with a self-reported confidence score (0–100). Board-certified U.S. medical oncologists independently reviewed outputs using a structured instrument; two disease specific expert oncologists evaluated each case. Outcomes included correctness and comprehensiveness (1–10 scales), hallucinations (factually fabricated or unsupported statements), NCCN traceability, potential patient harm, and clinician trust. Associations between accuracy and comprehensiveness were assessed using correlation coefficients. Inter-rater reliability was assessed using a two-way random-effects intraclass correlation coefficient (ICC). Results: ChatGPT-5 demonstrated higher mean correctness (8.65 vs 4.68) and comprehensiveness (8.68 vs 5.22) scores compared with MedGemma 27B. Accuracy and comprehensiveness were strongly correlated overall (Pearson r = 0.93, p < 0.001), with significant model-specific correlations (ChatGPT-5 r = 0.86, p < 0.001; MedGemma r = 0.77, p < 0.001). Hallucinations occurred less frequently with ChatGPT-5 (12.3% vs 65%), and NCCN-traceable recommendations were more common (75.4% vs 36.7%). Responses judged as potentially harmful occurred in 18.5% of ChatGPT-5 outputs versus 70% of MedGemma outputs. Clinician trust favored ChatGPT-5 (84.6% vs 15%). Inter-rater reliability improved with rater averaging (ICC(A,k): correctness 0.72; comprehensiveness 0.64). Conclusions: In expert-reviewed GI and GU oncology cases, ChatGPT-5 demonstrated higher clinical accuracy, comprehensiveness, and guideline alignment than a medical-specific LLM; however, a substantial rate of hallucinations and potentially harmful recommendations persisted across models. These findings underscore that, despite performance differences, current LLMs require rigorous clinician oversight and should not be used as standalone decision-support tools in oncology.
Real-world safety of adoptive cellular therapy with lifileucel in patients with advanced melanoma.
Haugh, Alexandra, Aboelatta, Mohamed A. , Ward, Kimberly, Shetty, Namrata, Chau, Jamie, Kalos, Denise , Frigault, Matthew J., Sullivan, Ryan J., Ma, Barbara T., Sarnaik, Amod, Jakub, James W., Seetharam, ­Mahesh , Karapetyan, Lilit, Lawrence, Donald P. , Cohen, Sonia , Boland, Genevieve M. , Frigault, Matthew J. , Sullivan, Ryan J. , Khushalani, Nikhil I. , Sarnaik, Amod A. , Johnson, Jeffrey A. , Doonan, Bently P. , Jakub, James W. , Dudek, Arkadiusz Z. , Karapetyan, Lilit

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 9510-9510

10.1200/jco.2026.44.16_suppl.9510 Get It

9510 Background: Although acute toxicities associated with adoptive cellular therapy using lifileucel are well described and largely occur within the first 2 weeks of treatment, adverse events beyond this early window remain incompletely characterized. We sought to characterize treatment-related adverse events (AEs) with emphasis on those starting or persisting ≥2 weeks after lifileucel infusion. Methods: We conducted a retrospective multicenter study across three centers (Moffitt Cancer Center, Massachusetts General Hospital, and Mayo Clinic). Patients with advanced melanoma treated with lifileucel were included. The primary endpoint was incidence and characterization of AEs occurring or persisting ≥2 weeks after standard of care lifileucel infusion. Results: Among 79 patients (median follow-up 11 months [95% CI, 9.6–15]), median age was 63 years (range 30–79), 59% were male (n = 47), 41% were female (n = 32), and ECOG PS was 0–1 in 98%. Patients received a median of 5 IL-2 doses (range 0–6). Of 79 patients, 78 experienced treatment-related adverse events that either persisted or occurred >2 weeks after cell infusion. A total of 308 delayed treatment-related adverse events were identified; 96 were new events (31%) and 212 (69%) were continued toxicities that started < 2 weeks after cell infusion. Lymphopenia was the most common delayed or persistent toxicity, occurring in a majority of patients (n = 68/79, 86%). Treatment-associated anemia (n = 59/79, 75%), fatigue (n = 56/79, 71%) and thrombocytopenia (n = 24/79, 30%) were also common. Viral infections occurred in 9.0% (n = 7), including CMV/EBV viremia (n = 1) and respiratory or gastrointestinal viral infections (metapneumovirus, parainfluenza, SARS-CoV-2, and norovirus). Hemophagocytic lymphohistiocytosis (HLH) occurred in 2 patients (n = 2/79, 3%) and was fatal in both cases. No other toxicity related deaths were noted. Autoimmune toxicities directly attributable to TIL included vitiligo in 9% (n = 7; median onset 41 days), uveitis in 5% (n = 4; median onset 26 days), and sensorineural hearing loss in 1% (n = 1; onset 28 days). All patients underwent TIL infusion in the inpatient setting; a total of 14 of 79 patients (18%) were re-admitted after discharge due to treatment-related toxicity (median time from infusion 19 days). Conclusions: In this multicenter real-world cohort, toxicities persisting beyond two weeks were largely driven by lymphodepleting chemotherapy–associated immunosuppression and cytopenias. These findings highlight the importance of structured post-discharge monitoring and support ongoing efforts to de-intensify lymphodepleting chemotherapy to improve safety while maintaining clinical benefit.
CD4 T-cell reconstitution and CD4:CD8 inversion following lymphodepleting chemotherapy for tumor-infiltrating lymphocyte therapy in metastatic melanoma.
Aboelatta, Mohamed A. , Zarka, Jabra, Ward, Kimberly, Chen, Ruqin, Jakub, James W., Seetharam, ­Mahesh , Shetty, Namrata, Chau, Jamie, Kalos, Denise , Frigault, Matthew J., Ma, Barbara T., Sarnaik, Amod, Haugh, Alexandra, Karapetyan, Lilit, Zarka, Jabra , Zarka, Jabra G , Dudek, Arkadiusz Z. , Johnson, Jeffrey A. , Jakub, James W. , Lawrence, Donald P. , Cohen, Sonia , Boland, Genevieve M. , Frigault, Matthew J. , Khushalani, Nikhil I. , Sarnaik, Amod A. , Karapetyan, Lilit

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 9551-9551

10.1200/jco.2026.44.16_suppl.9551 Get It

9551 Background: Lymphodepleting (LD) chemotherapy is required prior to tumor-infiltrating lymphocyte (TIL) therapy, yet the depth, kinetics, and completeness of peripheral T-cell recovery in practice remain poorly defined. Using a pooled, multi-institution cohort, we characterized longitudinal CD4 and CD8 T-cell reconstitution and the prevalence of CD4 lymphopenia following TIL therapy. Methods: We conducted a retrospective multicenter study across Mayo Clinic, Moffitt Cancer Center, and Massachusetts General Hospital of patients with metastatic melanoma treated with TIL (N = 41, median follow-up 7.6 months). Absolute CD4 and CD8 T-cell counts and CD4:CD8 ratios were assessed at baseline (pre-LD), week 4, month 3, and month 6 post-TIL. Clinically significant CD4 lymphopenia was defined as CD4 < 200 cells/µL. All patients received Pneumocystis jirovecii and antiviral prophylaxis, with antibacterial and antifungal prophylaxis administered per institutional protocols. Post-TIL infections were recorded. Paired changes from baseline were evaluated using Wilcoxon signed-rank testing. Results: Median age was 65 years (range 35-79), and 68% were male. At baseline, 16 patients (39%) had CD4 counts below the institutional lower limit of normal prior to LD. Eighteen patients (44%) received bridging therapy prior to TIL and had lower baseline CD4 and CD8 counts compared with those who did not ( p < 0.05 for both); however, post-TIL CD4 and CD8 recovery trajectories did not differ between groups. CD4 counts declined sharply following LD and demonstrated incomplete and heterogeneous recovery. Median CD4 decreased from 490 cells/µL at baseline to 250 at week 4, 290 at month 3, and 220 at month 6, remaining significantly below baseline at all post-TIL timepoints ( p < 0.05). Clinically significant CD4 lymphopenia was observed in 45% (10/22) of evaluable patients at month 3 and in 50% (44%, 7/16) at month 6. In contrast, CD8 counts increased early after TIL (median 240 to 590 cells/µL at week 4; p = 0.004) and remained higher than baseline at month 6. The CD4:CD8 ratio inverted from a median of 2.02 at baseline to 0.46 at week 4 and remained below 1.0 through month 6, reflecting sustained CD4 suppression despite CD8 recovery. Post-TIL infections occurred despite widespread prophylaxis, including bacterial (13%), viral (10%), and fungal (4.9%) infections. Conclusions: In a multi-institution cohort, LD chemotherapy preceding TIL is associated with profound and prolonged CD4 T-cell suppression, persistent CD4:CD8 inversion, and a high prevalence of CD4 < 200 cells/µL through 6 months. These findings identify delayed immune reconstitution as a common and clinically relevant consequence of TIL therapy and support prospective optimization of antimicrobial prophylaxis duration, vaccination timing, and immune monitoring strategies.
Age and frailty analyses of transplant-ineligible (TIE) patients (pts) with newly diagnosed multiple myeloma (NDMM) in the phase 3 MAIA and CEPHEUS trials of daratumumab + lenalidomide-dexamethasone (Rd) and bortezomib-Rd (VRd).
Venner, Christopher P., Zweegman, Sonja, Kumar, Shaji, Facon, Thierry, Perrot, Aurore, Moreau, Philippe, NS, Raje, Hulin, Cyrille, Hungria, Vania, Cohen, Yaël , Goldschmidt, H, Wang, George C., Bolyard, Kasey, Lopez-Masi, Lorena, Loi, Matteo, Borgsten, Fredrik, Rowe, Melissa, Bahlis, Nizar Jacques J., Usmani, Saad Z., Zweegman, Sonja , Kumar, Shaji , Facon, Thierry T.F. , Perrot, Aurore , Moreau, Philippe , Hulin, Cyrille , Basu, Supratik , Goldschmidt, Hartmut , Bahlis, Nizar Jacques , Usmani, Saad Z.

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 7569-7569

10.1200/jco.2026.44.16_suppl.7569 Get It

7569 Background: MAIA and CEPHEUS trials demonstrated that daratumumab (Dara) with standard of care (SOC) VRd or Rd significantly improved clinical outcomes versus SOC in TIE NDMM. Here we describe efficacy and safety in TIE pts from both trials by age and baseline (BL) frailty using the latest data cuts. Methods: Pts were randomized 1:1 to DRd (n=368) or Rd (n=369) in MAIA and 1:1 to DVRd (n=144) or VRd (n=145) in CEPHEUS. Progression-free survival (PFS), complete response or better (≥CR), overall MRD negativity (neg) at 10 -5 with ≥CR, sustained MRD neg with ≥CR (confirmed MRD neg ≥12 ± 1 months [mo] apart without MRD positivity in between), and safety were assessed by age (<70, 70–<75, or ≥75 years [y]) and BL frailty (assessed by IFM simplified frailty score: 0–1, non-frail; ≥2, frail). Results: Median follow-up was 64.5 mo in MAIA and 76.0 mo in CEPHEUS. In MAIA, 155 (21%) pts were <70 y, 261 (35%) 70–<75 y, and 321 (44%) ≥75 y; 341 (46%) pts were frail, 88.0 % of whom were ≥70 y. In CEPHEUS TIE pts, 70 (24%) pts were <70 y, 133 (46%) 70–<75 y, and 86 (30%) ≥75 y; 83 (29%) pts were frail, 86% of whom were ≥70 y. DRd or DVRd improved PFS, MRD neg rates, sustained MRD neg rates, and ≥CR rates vs Rd or VRd arms across age and frailty subgroups in both trials (Table). Safety was consistent with established individual drug profiles, and adverse event rates were generally comparable across treatment arms and subgroups within both trials. Additional data on patient-specific factors relevant to these subgroups will be presented. Conclusions: Dara-based regimens improved efficacy outcomes across subgroups in MAIA and CEPHEUS trials, reinforcing Dara-based regimens as SOC in TIE NDMM regardless of age or frailty. These data offer clinically relevant insights to help guide treatment selection for TIE pts. Clinical trial information: NCT03652064 ; NCT02252172 . PFS, hazard ratio (95% CI) ≥CR rate, % MRD neg with ≥CR (10 -5 ) rate, % Sustained MRD neg with ≥CR (10 -5 ) rate, % Age/ Frailty status MAIA* CEPHEUS** MAIA* CEPHEUS ** MAIA* CEPHEUS** MAIA* CEPHEUS ** <70 y 0.35 (0.21–0.56) 0.60 (0.31–1.18) 56.4 vs 31.2 85.7 vs 68.6 35.9 vs 11.7 74.3 vs 42.9 25.6 vs 3.9 62.9 vs 28.6 70–<75 y 0.64 (0.45–0.89) 0.60 (0.37–0.99) 56.2 vs 31.3 77.9 vs 69.2 36.2 vs 12.2 55.9 vs 47.7 20.8 vs 5.3 45.6 vs 38.5 ≥75 y 0.59 (0.44–0.79) 0.46 (0.22–0.94) 44.4 vs 28.6 80.5 vs 44.4 26.9 vs 9.9 58.5 vs 26.7 13.8 vs 3.1 43.9 vs 15.6 Frail 0.64 (0.48–0.85) 0.62 (0.32–1.18) 44.8 vs 33.1 72.9 vs 54.3 25.6 vs 13.0 56.3 vs 34.3 15.7 vs 4.1 39.6 vs 17.1 Non-frail 0.48 (0.36–0.64) 0.51 (0.34–0.78) 56.6 vs 27.5 84.4 vs 63.6 37.8 vs 9.5 63.5 vs 41.8 21.4 vs 4.0 54.2 vs 32.7 *MAIA: DRd vs Rd; **CEPHEUS: DVRd vs VRd.